$STIM

Neuronetics, Inc.

Neuronetics develops and sells the NeuroStar Advanced Therapy System, an office-based, non-invasive transcranial magnetic stimulation treatment for mental health conditions. The system is FDA-cleared for adults with major depressive disorder who have not improved satisfactorily with prior antidepressant medication, as an adjunct for adults with obsessive-compulsive disorder, and for certain adolescent patients with major depressive disorder. Neuronetics sells systems and recurring treatment sessions, along with service, repair and extended warranty contracts, and provides practice development, training, reimbursement and support services. It also operates Greenbrook, a wholly owned subsidiary that runs outpatient treatment centers offering NeuroStar therapy, SPRAVATO and medication management. Greenbrook operates 93 Treatment Centers and supports healthcare provider practice groups. Neuronetics primarily sells to psychiatrists in the United States, with primary care physicians and pain management specialists representing a smaller share of its customer base. It also markets products in select international markets through independent distributors, including Japan, where it has an exclusive distribution agreement. Neuronetics is headquartered in Malvern, Pennsylvania.

2
0
2
$120K
$4.5M
Chernett Jorey
0%
See all $STIM insider activity →
Med

Yeti downgraded, Humana upgraded: Wall Street's top analyst calls

RBC upgraded Humana (HUM) to Outperform with a $563 target, citing earnings potential. TD upgraded SPXC to Buy with a $200 target. Phillip upgraded ABNB to Neutral with a $184 target, expecting higher revenue growth. Gordon Haskett upgraded TXRH to Buy with a $220 target. Mizuho double upgraded VIK to Outperform with a $120 target. Goldman downgraded YETI to Neutral with a $41 target. KeyBanc downgraded FMC to Sector Weight.

William Blair initiates Neuronetics stock at Outperform on strategy shift

William Blair initiated coverage on Neuronetics Inc. (NASDAQ:STIM) with an Outperform rating, citing positive results from new strategies. The company's NeuroStar system is now offered through flexible purchasing models, and Greenbrook clinics are focusing on efficiency. Sales grew 11% YoY in Q2 and Q3 2026, with adjusted EBITDA improving to $2 million from negative $10 million YoY.

Chernett Jorey sold $4.5M of STIM

Chernett Jorey sold 3,335,411 shares of Neuronetics, Inc. (STIM) at an average of $1.34 ($1.15–$2.39, $4.48M total) across 5 trades over 2026-11-06 to 2026-11-13.

STIM sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 4 news stories mentioning STIM (Neuronetics, Inc.). Coverage has been balanced: 2 bullish, 0 neutral, and 2 bearish.

Recent STIM coverage spans corporate actions, financial news and insider activity.

In the last 30 days, STIM insiders filed 7 SEC Form 4 transactions — 2 purchases ($120K) and 5 sales ($4.5M). The most active reporter was Chernett Jorey with 7 filings.

What's driving STIM

AlphAI scores every news story that mentions STIM with an AI model for sentiment and relevance, and aggregates insider trades from Neuronetics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $STIM

Score

Yeti downgraded, Humana upgraded: Wall Street's top analyst calls

RBC upgraded Humana (HUM) to Outperform with a $563 target, citing earnings potential. TD upgraded SPXC to Buy with a $200 target. Phillip upgraded ABNB to Neutral with a $184 target, expecting higher revenue growth. Gordon Haskett upgraded TXRH to Buy with a $220 target. Mizuho double upgraded VIK to Outperform with a $120 target. Goldman downgraded YETI to Neutral with a $41 target. KeyBanc downgraded FMC to Sector Weight.

$STIMMedOffering· proposed

Neuronetics, Inc. (STIM): Entry into a Material Definitive Agreement

Neuronetics, Inc. (STIM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Neuronetics Announces Proposed Public Offering of Common Stock MALVERN, Pa., November 10, 2026 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health and provider of NeuroStar ® TMS technology an

$STIMMedDebt financing· $15M

Neuronetics, Inc. (STIM): Entry into a Material Definitive Agreement

Neuronetics, Inc. (STIM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. As previously disclosed, on July 25, 2024, Neuronetics, Inc. (the “Company”) entered into a Credit Agreement and Guaranty (as amended, the “Existing Credit Agreement”) with Perceptive Credit Holdings IV, LP (“Perceptive”), as

Neuronetics stock tumbles 10% on stock offering launch

Neuronetics Inc (STIM) shares dropped 10% in after-hours trading after announcing a public stock offering and a credit agreement amendment. The company aims to sell shares with a 30-day option for underwriters to buy 15% more. The amendment reduces revenue covenants if certain conditions are met by November 30, 2026, addressing going concern risks. William Blair, BTIG, and Canaccord Genuity are managing the offering.

Related tickers